Core - Pathology

Furth, Emma E.

Abstract

Core D will serve as the pathology section serving as the resource for the acquisition and tissue based evaluation of patient material (Project 3 and Core C), the development and implementation of immunohistochemistry (Projects 1,2,3,4 and Core C) and in situ hybridization studies (Projects 1,2 and 3). With available antibodies to the GA 733 antigen provided by Core B, Core D will perform and evaluate its expression in patient tumors prior to their entry to the vaccine trail as not all colonic carcinomas express this antigen. Core D will interact actively with all projects and Core C with detailed morphologic and immunohistochemical evaluation of antibodies to the GA733 antigen in both patient material and patient tumors grown in SCID mice. Additionally, Core D will evaluate the tissue reactivity of GA 733 directed antibodies from patients with ulcerative colitis, healthy donor, and colorectal cancer patients before and after vaccination (Project 4). Core D will provide histologic, immunohistochemical, and tissue based molecular biologic studies of skin specimens from mice and humans injected intradermally with Ad mEGP or AdGA733-2. In situ hybridization will be provided to distinguish humans from mouse tissue in SCID mice transplantation studies. Additionally, Core D will serve in the evaluation of mouse tissue for potential toxicity of adenovirus vaccines (Project 2).

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Program Projects (P01)
• Project #: 5P01CA074294-05
• Application #: 6563880
• Project Start: 2002-01-17
• Project End: 2002-12-31
• Support Year: 5
• Fiscal Year: 2002
• Total Cost: $228,401

Institution

• Name: Wistar Institute
• DUNS #: 042250712
• City: Philadelphia
• State: PA
• Country: United States
• Zip Code: 19104

Publications

Berencsi, Klara; Rani, Pyapalli; Zhang, Tianqian et al. (2011) In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med 9:33

Swoboda, Rolf K; Somasundaram, Rajasekharan; Caputo, Laura et al. (2010) Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. Int J Cancer 127:1124-30

Kalabis, Jiri; Li, Gang; Fukunaga-Kalabis, Mizuho et al. (2008) Endothelin-3 stimulates survival of goblet cells in organotypic cultures of fetal human colonic epithelium. Am J Physiol Gastrointest Liver Physiol 295:G1182-9

Berencsi, Klara; Meropol, Neal J; Hoffman, John P et al. (2007) Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother 56:359-70

Furth, Emma E; Li, Jian; Purev, Enkhtsetseg et al. (2006) Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. Cancer Immunol Immunother 55:528-37

Gutzmer, Ralf; Li, Wei; Sutterwala, Shaheen et al. (2004) A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 173:1023-32

Birebent, Brigitte; Mitchell, Edith; Akis, Nese et al. (2003) Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 21:1601-12

Schaider, Helmut; Oka, Masahiro; Bogenrieder, Thomas et al. (2003) Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103:335-43

Armstrong, Andrew; Eck, Stephen L (2003) EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:320-6

Zaloudik, Jan; Li, Weiping; Jacob, Lutz et al. (2002) Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther 9:382-9